Global Kidney Cancer Drugs Market Report 2024

Kidney Cancer Drugs Global Market Report 2023 – By Type (Renal Cell Carcinoma, Urothelial Carcinoma, Others (Renal Sarcoma, Renal Lymphoma)), By Product (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Other Products), By End Users (Hospitals, Clinics, Research Center, Other EndUsers) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Kidney Cancer Drugs Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Kidney cancer drugs that can treat kidney cancer. Because they can reach cancer cells practically anywhere in the body, these treatments are known as systemic therapy. Several different types of medications may be used, depending on the type of kidney cancer. It functions by stopping tyrosine kinases, which are crucial proteins in cancer cells that aid in growth and survival, or angiogenesis, the development of new blood vessels that feed malignancies.

The main types of kidney cancer are renal cell carcinoma (RCC), urothelial carcinoma, and others (renal sarcoma, renal lymphoma). Renal cell carcinoma is a disease in which malignant (cancer) cells form in the kidney's tubules. The different products involved are Nexavar (sorafenib), Sutent (sunitinib), Afinitor (everolimus), Voting (pazopanib), Avastin (bevacizumab), Inlyta (axitinib), to rising (temsirolimus), Proleukin (aldesleukin), and others that are used by hospitals, clinics, research centres, etc.

The global kidney cancer drugs market is segmented -

1) By Type: Renal Cell Carcinoma, Urothelial Carcinoma, Others (Renal Sarcoma, Renal Lymphoma)

2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Other Products

3) By End Users: Hospitals, Clinics, Research Center, Other End-Users

The global kidney cancer drugs market size will grow from $7.41 billion in 2022 to $7.81 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global kidney cancer drugs market is expected to grow to $9.33 billion in 2027 at a CAGR of 4.5%.

The rise in the incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Changes in the lifestyle of people, the consumption of tobacco, and an unhealthy diet are some factors that contribute to the growth of these renal cancer cells. For instance, in January 2022, according to the American Cancer Society, a US-based health organization that works for cancer elimination, there will be 79,000 new instances of kidney cancer diagnosed (50,290 men and 28,710 women), and 13,920 people will pass away from the disease (8,960 men and 4,960 women). The majority of people are diagnosed between the ages of 65 and 74, with an average diagnosis age of 64. When a person is under the age of 45, kidney cancer is quite rare. thus driving the growth of the kidney cancer drugs market.

Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis Inc., F. Hoffmann-La Roche Ag, Genentech Inc., Glaxosmithkline PLC., Active Biotech, Amgen, Thermo Fisher Scientific Inc., Bristol-Myers Squibb, Eisai, Roche, Cipla Limited, Onyx, Abbott Laboratories, Aveo Pharmaceuticals, Immatics Biotechnologies, Prometheus Laboratories, Argos Therapeutics, Myriad Genetics Inc., NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina Inc. and Quest Diagnostics Incorporated.

The increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective. Also, targeted drugs are used post kidney cancer surgery to prevent the re-occurrence of kidney cancer. Conventional chemical drugs cannot be used in the same way. Also, targeted therapies for kidney cancer have illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials. In a study conducted by Pfizer, using targeted therapy had more chances of tumor shrinkage than using chemical drugs. Targeted drugs, axitinib and Pembrolizumab are being used to treat stage IV kidney cancer which especially attacks the spreading points of cancer. Thus, the pharmaceutical industry is embracing targeted therapies because of the above-mentioned benefits. Therefore, hindering the growth of the kidney cancer drugs market.

The use of combination therapy is trending in the kidney (renal) cancer drug market. Combination therapy combines the effects of various drugs, thereby reducing the likelihood of cancer-resistant cells developing. The improved understanding of renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment, the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood, are combined with inhibitors of the mammalian target of rapamycin (mTOR), which helps promote cellular biogenesis. For instance, in November 2021, Merck & Co., Inc., a US-based research-oriented biopharmaceutical company, announced that the anti-PD-1 drug KEYTRUDA from Merck has received FDA approval for the adjuvant treatment of renal cell carcinoma (RCC) patients who are at intermediate-high or high risk of recurrence after nephrectomy or after nephrectomy with resection of metastatic lesions.

The kidney cancer drugs market is governed by the regulatory framework of agencies such as the Food and Administration Agency (FDA) and the American Society of Clinical Oncology (ASCO). The FDA's recommendation for the kidney cancer drugs industry in the form of guidelines are mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312, which contains sub-parts from subpart 'A' to subpart 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed at treating persons with life-threatening illnesses such as kidney cancer. The subpart 'E' also includes guidelines for the monitoring and evaluation of clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in the kidney cancer drugs industry are required to abide by the regulations under FDA.

In October 2022, LG Chem, Ltd., a South Korea-based chemical company, acquired AVEO Oncology for $566 million. The acquisition gives LG Chem's Life Sciences Division a commercial footprint in the United States, diversifies its pipeline with a wide range of oncology treatments, and speeds up LG Chem's efforts to deliver ongoing growth. Both companies anticipate establishing a global oncology organisation with a strong portfolio of cutting-edge products supported by full capabilities from discovery to clinical, biologics manufacturing, and U.S. commercialization, at a scale capable of broadening access to treatment options. AVEO Oncology is a US-based, commercial-stage, oncology-focused biopharmaceutical company dedicated to providing cancer patients with drugs that improve their quality of life.

North America was the largest region in the kidney cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the global kidney cancer drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The kidney cancer drugs market consists of sales of axitinib (Inlyta), cabozantinib (cabometyx), and pazopanib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The kidney cancer drugs market research report is one of a series of new reports from The Business Research Company that provides kidney cancer drugs market statistics, including kidney cancer drugs industry global market size, regional shares, competitors with a kidney cancer drugs market share, detailed kidney cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the kidney cancer drugs industry. This kidney cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

    Table Of Contents

    1. Executive Summary

    2. Kidney Cancer Drugs Market Characteristics

    3. Kidney Cancer Drugs Market Trends And Strategies

    4. Kidney Cancer Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Kidney Cancer Drugs Market

    4.2 Ukraine-Russia War Impact On Kidney Cancer Drugs Market

    4.3 Impact Of High Inflation On Kidney Cancer Drugs Market

    5. Kidney Cancer Drugs Market Size And Growth

    5.1. Global Kidney Cancer Drugs Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Kidney Cancer Drugs Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Kidney Cancer Drugs Market Segmentation

    6.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Renal Cell Carcinoma

    Urothelial Carcinoma

    Others (Renal Sarcoma, Renal Lymphoma)

    6.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Nexavar (Sorafenib)

    Sutent (Sunitinib)

    Afinitor (Everolimus)

    Votrient (Pazopanib)

    Avastin (Bevacizumab)

    Inlyta (Axitinib)

    Torisel (Temsirolimus)

    Proleukin (Aldesleukin)

    Other Products

    6.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospitals

    Clinics

    Research Center

    Other End Users

    7. Kidney Cancer Drugs Market Regional And Country Analysis

    7.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Kidney Cancer Drugs Market

    8.1. Asia-Pacific Kidney Cancer Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Kidney Cancer Drugs Market

    9.1. China Kidney Cancer Drugs Market Overview

    9.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Kidney Cancer Drugs Market

    10.1. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.3. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Kidney Cancer Drugs Market

    11.1. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.3. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Kidney Cancer Drugs Market

    12.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Kidney Cancer Drugs Market

    13.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Kidney Cancer Drugs Market

    14.1. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.3. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Kidney Cancer Drugs Market

    15.1. Western Europe Kidney Cancer Drugs Market Overview

    15.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Kidney Cancer Drugs Market

    16.1. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.3. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Kidney Cancer Drugs Market

    17.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Kidney Cancer Drugs Market

    18.5. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.6. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.7. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Kidney Cancer Drugs Market

    19.1. Eastern Europe Kidney Cancer Drugs Market Overview

    19.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Kidney Cancer Drugs Market

    20.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Kidney Cancer Drugs Market

    21.1. North America Kidney Cancer Drugs Market Overview

    21.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Kidney Cancer Drugs Market

    22.1. USA Kidney Cancer Drugs Market Overview

    22.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Kidney Cancer Drugs Market

    23.1. South America Kidney Cancer Drugs Market Overview

    23.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Kidney Cancer Drugs Market

    24.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Kidney Cancer Drugs Market

    25.1. Middle East Kidney Cancer Drugs Market Overview

    25.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Kidney Cancer Drugs Market

    26.1. Africa Kidney Cancer Drugs Market Overview

    26.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles

    27.1. Kidney Cancer Drugs Market Competitive Landscape

    27.2. Kidney Cancer Drugs Market Company Profiles

    27.2.1. Bayer AG

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Pfizer Inc

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Novartis International AG

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Exelixis, Inc

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. F. Hoffmann-La Roche Ag

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Kidney Cancer Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market

    30. Kidney Cancer Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 47: North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 48: North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 49: North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 50: USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 51: USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 52: USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 53: South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 54: South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 55: South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 56: Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 57: Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 58: Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 59: Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 60: Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 61: Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 62: Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 63: Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 64: Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 65: Bayer AG Financial Performance
  • Table 66: Pfizer Inc Financial Performance
  • Table 67: Novartis International AG Financial Performance
  • Table 68: Exelixis, Inc Financial Performance
  • Table 69: F. Hoffmann-La Roche Ag Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 47: North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 48: North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 49: North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 50: USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 51: USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 52: USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 53: South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 54: South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 55: South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 56: Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 57: Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 58: Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 59: Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 60: Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 61: Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 62: Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 63: Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 64: Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 65: Bayer AG Financial Performance
  • Figure 66: Pfizer Inc Financial Performance
  • Figure 67: Novartis International AG Financial Performance
  • Figure 68: Exelixis, Inc Financial Performance
  • Figure 69: F. Hoffmann-La Roche Ag Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report